Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
Henk M. Lokhorst
Consultant or Advisory Role - Genmab; Janssen
Research Funding - Genmab; Janssen
Jacob Laubach
Research Funding - Novartis; Onyx
Hareth Nahi
No relevant relationships to disclose
Torben Plesner
Consultant or Advisory Role - Genmab; Janssen
Honoraria - Celgene; Genmab; Janssen
Research Funding - Janssen
Expert Testimony - Takeda
Peter Gimsing
No relevant relationships to disclose
Markus Hansson
No relevant relationships to disclose
Monique Minnema
Honoraria - Janssen-Cilag
Ulrik Niels Lassen
No relevant relationships to disclose
Jakub Krejcik
No relevant relationships to disclose
Tahamtan Ahmadi
Employment or Leadership Position - Janssen Research & Development
Steen Lisby
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Linda Basse
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Nikolai C. Brun
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Paul G. Richardson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Genmab; Johnson & Johnson; Millennium; Novartis